Searched for
LUPIN REVENUE
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Lupin shares jump 2% as Q2 PAT soars 73% YoY to Rs 1,485 croreLupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales...
- Lupin shares drop 3% after Q3 resultsShares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged 102.7%, reach...
- Lupin surges 4% on positive brokerage commentary post Q2Macquarie maintained its 'outperform' rating on the stock with a 12-month target price of ₹790 per share as profitability missed estimates ...
- Lupin remains a ‘sell’ on Q4 miss; Target prices cutCitigroup and Elara have maintained sell rating and Antique has reiterated its hold rating.
- Lupin net skids, says Gavis deal ‘shy’ of expectationsThe business fell 13.2% to Rs 1,900.7 crore from a year earlier and contributed 46% of sales.
- Stock pick of the week: Why analysts are bullish on LupinIn addition to growth in sales in respective markets, favourable currency movement has also helped Lupin to achieve high growth.
- US Generic launches are key to Lupin growthLupin's revenue grew 5% yearon-year to Rs 3,144.9 crore during the December 2014 quarter, much lower than the analysts' expectation of 12-1...
- Looking to acquire companies and launch new products in India: LupinHomegrown drug major Lupin is looking to acquire companies and launch new products in the domestic market as it aims to scale up its Indian...
- Lupin Pharma's India business a cause for concernLupin Pharma’s underperformance in the domestic market may rein in investors’ bullish stance on the share — a hitherto darling of the India...
- Lupin scouts for buys in Latin AmericaThe company expects to launch 10 new products in Japan this year, considered the most difficult of three developed pharmaceutical markets -...
Load More
